Clinical trial · Interventional
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma
NCT01677468CI-TRIAL-00007931unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Transarterial Chemoembolization | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Complete embolization | Procedure | — | UNRESOLVED |
| Intermediate embolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intermediate embolization
- description
- TACE with substatsis using gelfoam
- interventionNames
- Procedure: Intermediate embolization
- type
- ACTIVE_COMPARATOR
- label
- Complete embolization
- description
- TACE with complete embolization using gelfoam
- interventionNames
- Procedure: Complete embolization
Primary outcomes (4)
- measure
- Survival rate of the subjects
- timeFrame
- 6 months after TACE
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * age over 18 * ECOG performance status 0-2 * Hepatocellular carcinoma diagnosed histologically or clinically * Tumor numbers of 5 or less * No history of treatment for hepatocellular carcinoma * Patients with informed consent Exclusion Criteria: * Extrahepatic metastasis * Rupture of hepatocellular carcinoma * Infiltrative hepatocellular carcinoma * Malignancy other than hepatocellular carcinoma
References
Publications (0)
Data not yet available
No reference posted for this study.